Wayne State Receives $140,000 Grant for Esophageal Cancer
A two-year Department of Defense award will fund preclinical research into a ferroptosis-based therapy for esophageal cancer.
Updated on Nov. 19, 2026 in Diseases

Wayne State University researchers have received a two-year, $140,000 award from the U.S. Department of Defense to study ferroptosis as a treatment approach for esophageal cancer. The project will test the experimental compound ML210 to inhibit GPX4 in laboratory and patient-derived tumor models.
Why it matters
Existing esophageal cancer therapies too often fail to prevent recurrence, so new approaches are needed for patients who have limited options. The preclinical work could provide proof-of-concept data supporting future translational development in Detroit and beyond.
The award is a $140,000 Department of Defense grant over two years, funded under the Rare Cancers Research Program Concept Award mechanism. Whether inhibiting GPX4 with ML210 will produce a therapeutic effect in esophageal cancer models remains unknown until the study is completed.
The players
Wayne State University School of Medicine
The medical school of Wayne State University in Detroit, home to the Department of Oncology conducting this research.
Karmanos Cancer Institute
A comprehensive cancer center in Detroit affiliated with Wayne State University that conducts cancer research and patient care.
The details
Led by Dr. Husain Yar Khan, assistant professor in the Department of Oncology at Wayne State University School of Medicine, with co-investigators Dr. Asfar Azmi and Dr. Yang Shi, the project is titled "Inducing Ferroptosis Through GPX4 Inhibition as a Novel Therapeutic Approach for Esophageal Cancer." The team will evaluate GPX4 inhibition in laboratory models and patient-derived tumor models.
Timeline
The two-year award period begins following the November 2026 announcement.
Big Picture
The project builds on the growing body of research into ferroptosis, a cell-death pathway that depends on GPX4 antioxidant defenses, and applies that mechanism to esophageal cancer. Its findings could offer a blueprint for other rare cancers that rely on the same antioxidant machinery.
For patients with esophageal cancer, this research is at the laboratory stage and will not change current treatment options. Any future therapy would require clinical trials before it could reach patients.
The takeaway
Preclinical research funded by federal grants is how new cancer therapies begin, and results from this study will show whether GPX4 inhibition merits clinical testing. Readers tracking esophageal cancer progress should watch for published findings from the Wayne State team.
Further reading
Explore more cancer research coverage on Wayne State's oncology work in Detroit.
Source note: This article includes information reported by News-Medical.






